Since 1919, Pfanstiehl has been a trusted U.S.-based cGMP manufacturer of high-purity, low-endotoxin, and low-metal parenteral excipients and biopharma components. Our portfolio includes Trehalose, Sucrose, Mannitol, Maltose, Galactose (non-animal), Mannose, and amino acids like Arginine, Histidine, Methionine, and Glutamine. These ingredients are critical stabilization components or process materials for Biologics, Biosimilars, Vaccines, Cell Culture Media, and Injectables (liquid & lyophilized), supporting many approved and marketed Biopharmaceuticals worldwide.

New Launches: Methionine (M168) and Glutamine (G167)

Pfanstiehl's state-of-the-art facility in Waukegan, Illinois, boasts extensive manufacturing capacity and industry-leading ICH-Q7 GMP quality standards. All products are multi-compendial, meeting stringent regulatory requirements. We also provide full technical and regulatory support, including DMF filings in the U.S. and China. 

From isolation and purification to custom synthesis and scale-up development, Pfanstiehl delivers unparalleled quality and consistency in injectable formulation ingredients and active pharmaceutical ingredients. When you need excellence, rely on Pfanstiehl.

Pfanstiehl, Inc.
1219 Glen Rock Avenue
Waukegan, IL 60085-6230

USA Telephone: +1 847-623-0370
Toll Free Number: +1 800-383-0126
Europe Telephone: +41 41 755 40 54

Email: cs@pfanstiehl.com
Website: www.pfanstiehl.com

Go to article: Home | Enhancing therapy adherence with prodrugsGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: CytivaGo to article: NiproGo to article: Laboratorios Argenol Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Avenga Company InsightGo to article: Lactalis IngredientsGo to article: BSP PharmaceuticalsGo to article: AlfatestLABGo to article: Alphial Company InsightGo to article: In DepthGo to article: Prodrugs and patents: Enhancing therapy adherence and reducing side effectsGo to article: Are PBMs to blame for high drug prices in the US?Go to article: Into the unknown: how quickly can vaccines be developed for Disease XGo to article: US negotiations for first round of drugs reveal $6bn in Medicare savings Go to article: Emerging microbiome market – unlocking new frontiers Go to article: Build or buy? Key considerations for in-house manufacturingGo to article: BiomeBank Company InsightGo to article: IMP Pharmaceutical ServicesGo to article: XylemGo to article: Sponsored SupplementsGo to article: Techniconsult Firenze Company InsightGo to article: PfanstiehlGo to article: Duoject Medical Systems Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Zenatek Company InsightGo to article: BEA TechnologiesGo to article: Next issue